Brickell Biotech Earnings Estimate

BBI
 Stock
  

USD 4.41  0.43  10.80%   

Many public companies, such as Brickell Biotech, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Brickell Biotech's earnings estimates, investors can diagnose different trends across Brickell Biotech's analyst sentiment over time as well as compare current estimates against different timeframes.
Brickell Biotech is projected to generate -0.53 in earnings per share on the 31st of December 2021. Brickell Biotech earnings estimates module stress-tests analyst consensus about projected Brickell Biotech EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Continue to Trending Equities.
  
Refresh
The current Gross Profit is estimated to increase to about 414.6 K, while Profit Margin is projected to decrease to (100.28) .

Brickell Biotech Earnings Estimation Breakdown

Calculation of earning per share of Brickell Biotech is based on official Zacks consensus of 0 analysts regarding Brickell Biotech future annual earnings. Given the historical accuracy of 60.29%, the future earnings per share of Brickell Biotech is estimated to be -0.53 with the lowest and highest values of -0.53 and -0.53, respectively. Please note that this consensus of annual earnings estimates for Brickell Biotech is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS -0.42
-0.53
Lowest
Expected EPS -0.53
-0.53
Highest

Brickell Biotech Earnings Projection Consensus

Suppose the current estimates of Brickell Biotech's value are higher than the current market price of the Brickell Biotech stock. In this case, investors may conclude that Brickell Biotech is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Brickell Biotech's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

0

60.29%

-0.42

-0.53

Brickell Biotech Earnings History

Earnings estimate consensus by Brickell Biotech analysts from Wall Street is used by the market to judge Brickell Biotech's stock performance. The investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Brickell Biotech's upcoming profit reports and earnings-per-share forecasts but also compare them to our different valuation methods.

Brickell Biotech Quarterly Earnings Before Interest Taxes and Depreciation Amortization EBITDA

(9.4 Million)

The current Accumulated Retained Earnings Deficit is estimated to decrease to about (156.8 M). The current Earning Before Interest and Taxes EBIT is estimated to decrease to about (40.4 M) The current Weighted Average Shares is estimated to increase to about 86.7 M. The current Weighted Average Shares Diluted is estimated to increase to about 86.7 M.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Brickell Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Brickell Biotech in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.203.9814.30
Details
Intrinsic
Valuation
LowReal ValueHigh
0.203.9114.23
Details
Naive
Forecast
LowNext ValueHigh
0.105.0715.39
Details
1 Analysts
Consensus
LowTarget PriceHigh
4.004.004.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Brickell Biotech. Your research has to be compared to or analyzed against Brickell Biotech's peers to derive any actionable benefits. When done correctly, Brickell Biotech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Brickell Biotech.
Note that many institutional investors and large investment bankers can move markets due to the volume of Brickell assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Brickell Biotech. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Brickell stock price in the short term.

Brickell Biotech Earnings per Share Projection vs Actual

Actual Earning per Share of Brickell Biotech refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Brickell Biotech predict the company's earnings will be in the future. The higher the earnings per share of Brickell Biotech, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Brickell Biotech Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Brickell Biotech, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Brickell Biotech should always be considered in relation to other companies to make a more educated investment decision.

Brickell Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Brickell Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-12
2022-03-31-0.06-0.08-0.0233 
2022-03-15
2021-12-31-0.08-0.060.0225 
2021-11-09
2021-09-30-0.125-0.16-0.03528 
2021-08-12
2021-06-30-0.125-0.16-0.03528 
2021-05-13
2021-03-31-0.115-0.15-0.03530 
2021-03-09
2020-12-31-0.09-0.15-0.0666 
2020-11-12
2020-09-30-0.185-0.150.03518 
2020-08-12
2020-06-30None-0.4331None
2020-05-13
2020-03-31None-0.4506None
2020-03-18
2019-12-31None-1.37None
2019-11-13
2019-09-30None-1.6519None
2019-07-12
2019-06-30-0.77-0.770
2019-05-02
2019-03-31-1.26-1.47-0.2116 
2019-02-19
2018-12-31-1.19-1.190
2018-10-29
2018-09-30-1.54-0.491.0568 
2018-08-07
2018-06-30-1.89-1.540.3518 
2018-05-03
2018-03-31-0.63-2.03-1.4222 
2018-03-15
2017-12-31-0.73-1.47-0.74101 
2017-10-23
2017-09-30-1.75-1.89-0.14
2017-08-08
2017-06-30-0.25-0.3-0.0520 
2017-05-15
2017-03-31-0.18-0.25-0.0738 
2017-03-09
2016-12-31-0.21-0.25-0.0419 
2016-11-03
2016-09-30-0.24-0.240
2016-08-09
2016-06-30-0.28-0.140.1450 
2016-05-09
2016-03-31-0.4-0.260.1435 
2016-03-14
2015-12-31-0.2-0.26-0.0630 
2015-10-29
2015-09-30-0.35-0.22840.121634 
2015-07-30
2015-06-30-0.57-0.30.2747 
2015-05-08
2015-03-31-0.5-0.40.120 
2015-02-26
2014-12-31-0.47-0.5-0.03
2014-10-30
2014-09-30-0.47-0.5-0.03
2014-07-31
2014-06-30-3.27-3.5-0.23
2014-05-01
2014-03-31-3.5-2.80.720 
2014-02-12
2013-12-31-6.11-2.14.0165 
2013-10-31
2013-09-30-7.3-7.7-0.4
2013-08-01
2013-06-30-7.58-7.7-0.12
2013-05-09
2013-03-31-7.35-7.7-0.35
2013-02-06
2012-12-31-7-6.30.710 
2012-11-07
2012-09-30-6.44-6.30.14
2012-08-01
2012-06-30-4.55-6.3-1.7538 
2012-05-02
2012-03-31-5.460.19835.6583103 
2012-02-08
2011-12-31-8.12-6.31.8222 
2011-11-01
2011-09-3010.2715.45.1349 
2011-08-03
2011-06-30-8.17-8.4-0.23
2011-05-05
2011-03-31-7.56-8.4-0.8411 
2011-02-10
2010-12-31-8.26-6.31.9623 
2010-11-09
2010-09-30-9.57-8.41.1712 
2010-08-03
2010-06-30-8.96-10.5-1.5417 
2010-05-06
2010-03-31-9.38-10.5-1.1211 
2010-02-11
2009-12-31-9.27-9.8-0.53
2009-11-04
2009-09-30-9.27-9.8-0.53
2009-08-06
2009-06-30-10.67-9.80.87
2009-05-06
2009-03-31-13.12-14-0.88
2009-02-17
2008-12-31-16.1-15.40.7
2008-11-05
2008-09-30-14.7-16.8-2.114 
2008-08-05
2008-06-30-16.52-14.71.8211 
2008-05-08
2008-03-31-15.54-16.8-1.26
2008-02-21
2007-12-31-14.84-16.1-1.26
2007-10-31
2007-09-30-15.05-16.8-1.7511 
2007-08-07
2007-06-30-15.54-14.70.84
2007-05-03
2007-03-31-15.4-16.8-1.4
2007-02-20
2006-12-31-15.63-14.70.93
2006-11-02
2006-09-30-16.52-16.8-0.28
2006-08-01
2006-06-30-15.63-7.77.9350 
2006-05-02
2006-03-31-15.63-11.24.4328 
2006-02-14
2005-12-31-14.93-140.93
2005-11-01
2005-09-30-18.9-18.20.7
2005-08-02
2005-06-30-18.2-14.73.519 
2005-05-03
2005-03-31-18.2-22.4-4.223 
2005-02-15
2004-12-31-21-13.37.736 
2004-11-02
2004-09-30-21.7-14.7732 
2004-08-03
2004-06-30-25.67-16.19.5737 
2004-05-06
2004-03-31-24.73-31.5-6.7727 
2004-02-10
2003-12-31-27.65-24.53.1511 
2003-11-05
2003-09-30-19.6-12.6735 
2003-07-31
2003-06-30-23.1-23.8-0.7
2003-05-05
2003-03-31-24.03-23.10.93
2003-02-10
2002-12-31-26.6-27.3-0.7
2002-11-04
2002-09-30-28.23-217.2325 
2002-07-29
2002-06-30-25.2-17.57.730 
2002-05-06
2002-03-31-23.45-18.25.2522 
2002-02-11
2001-12-31-16.33-4.911.4369 
2001-11-05
2001-09-30-11.67-9.12.5722 
2001-08-06
2001-06-30-9.57-11.2-1.6317 
2001-05-07
2001-03-31-9.1-72.123 
2001-02-12
2000-12-31-6.77-7-0.23
2000-11-06
2000-09-30-10.15-6.33.8537 
2000-08-07
2000-06-30-4.2-2.81.433 
2000-05-01
2000-03-31-10.5-10.50
2000-02-14
1999-12-31-3.5-0.72.880 
1999-11-01
1999-09-30-14-12.61.410 
1999-08-02
1999-06-30-13.77-13.30.47
1999-05-03
1999-03-31-2.8-3.5-0.725 
1999-02-08
1998-12-31-9.8-9.10.7
1998-11-02
1998-09-30-12.95-7.75.2540 
1998-08-03
1998-06-30-12.6-13.3-0.7
1998-05-04
1998-03-31-5.6-3.52.137 
1998-02-09
1997-12-31-7-4.92.130 
1997-11-03
1997-09-301.05-0.7-1.75166 
1997-08-04
1997-06-30-13.65-10.53.1523 
1997-05-05
1997-03-31-13.3-9.14.231 
1997-02-10
1996-12-31-11.2-6.34.943 
1996-11-04
1996-09-30-12.6-9.82.822 
1996-08-01
1996-06-30-1.41.42.8200 
1996-05-01
1996-03-31-9.8-8.41.414 

About Brickell Biotech Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Brickell Biotech earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Brickell Biotech estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Brickell Biotech fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit-145.4 M-156.8 M
Earning Before Interest and Taxes EBIT-39.4 M-40.4 M
Earnings per Basic Share(0.49) (0.53) 
Earnings per Diluted Share(0.49) (0.53) 
Price to Earnings Ratio(0.47) (0.50) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-39.4 M-40.4 M
Earnings before Tax-39.5 M-40.5 M
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brickell Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Search Now

   

Equity Search

Search for actively traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Brickell Biotech Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
11.7 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.